Lisata Therapeutics, Inc. Announces Amendment and Waiver to Merger Agreement with Kuva Labs Inc. – Key Details for Investors
Lisata Therapeutics, Inc. (NASDAQ: LSTA) filed a Current Report on Form 8-K announcing significant amendments to its Agreement and Plan of Merger with Kuva Labs Inc. and Kuva Acquisition Corp. The amendments and associated waivers have critical implications for shareholders, particularly given the uncertainty around the financing for the pending tender offer and merger. Below are the key points and potential price-sensitive details from the filing.
Key Points in the Report
- Amendment to Merger Agreement: The “outside date” to complete the merger has been extended from July 6, 2026, to July 17, 2026. This extension provides more time for Kuva Labs and Kuva Acquisition Corp. (the “Parent” and “Purchaser”) to secure the necessary financing and fulfill all closing conditions.
- Uncommitted Financing: As of June 8, 2026, the Parent and Purchaser have not secured committed financing for the offer and merger. They have identified anticipated funding sources, including:
- Sale of up to \$25 million of convertible notes to funds managed by JBA Asset Management LLC (based on a non-binding indication of interest).
- Cash on hand.
- Potential debt/equity capital raises and revolving credit facilities.
However, the report explicitly states that these sources are not binding commitments and there is no assurance they will be available on the anticipated terms or at all.
- Obligation to Secure Alternative Financing: If any anticipated funding sources become unavailable, Purchaser is required to use its best efforts to obtain alternative financing sufficient to fund the offer and merger. Any material changes in funding sources must be disclosed to Lisata and, if required by law, through an amendment to the Schedule TO filed with the SEC.
- Disclosure Requirements: The absence of committed financing is considered material information for Lisata shareholders deciding whether to tender their shares. The Purchaser is obligated to continue disclosing the financing status, including any material changes, in accordance with SEC rules. If there are changes that materially affect the offer, amendments to the Schedule TO must be filed and the offer period must be extended as required.
- Termination Rights: Lisata may terminate the amendment and extension if Parent fails to make payments when due, or commits material breaches that adversely affect the transaction and fails to cure within two business days after written notice.
- Exhibit 2.1: The full text of the Amendment and Waiver to the Agreement and Plan of Merger is included as Exhibit 2.1 to the Form 8-K filing, providing further legal and operational detail for investors.
- Tender Offer Status: The tender offer referenced in the document has not yet commenced. If it does, Kuva Labs and Kuva Acquisition Corp. will file a Schedule TO with the SEC, and Lisata will file a Schedule 14D-9. These documents will contain crucial information for investors and will be made available free of charge on Lisata’s investor relations website and the SEC website.
Potentially Price-Sensitive Information
- Uncertainty Around Financing: The lack of committed financing introduces considerable risk to the completion of the tender offer and merger. If financing cannot be secured, the merger may not occur. This uncertainty may significantly impact Lisata’s share price as investors reassess the likelihood of the transaction closing.
- Extension of Deadline: The extension of the outside date signals that the parties are still working to finalize the transaction, but also highlights potential challenges and delays. Investors should monitor further disclosures for updates.
- Disclosure of Material Changes: Any future developments regarding financing will be disclosed via the SEC, which could lead to abrupt movements in share price depending on the nature of the updates.
- Cautionary Statements: The filing includes a section on forward-looking statements, warning investors about the risks and uncertainties associated with the transaction, including the possibility that the deal may not close, or milestone payments related to contingent value rights (CVRs) may never be achieved. These risks should be carefully considered by shareholders.
Important Information for Lisata Shareholders
- Shareholders should be aware of the uncommitted financing risk and the possibility that the transaction may not close if funding cannot be secured.
- The tender offer has not yet commenced. No action is required at this time, but shareholders should closely monitor company and SEC filings for updates and tender offer materials.
- Any decision to tender shares should be made only after reviewing the tender offer statement on Schedule TO and the solicitation/recommendation statement on Schedule 14D-9, if and when they are filed.
- Future press releases regarding the merger will be issued in accordance with Section 6.7 of the Merger Agreement, so shareholders should expect further communications if material developments occur.
Additional Details
- Lisata Therapeutics, Inc. is incorporated in Delaware, trades on the Nasdaq Capital Market under the ticker “LSTA,” and is headquartered at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.
- The Amendment and Waiver was signed by Mark Land, CEO of Kuva Acquisition Corp., and David J. Mazzo, Ph.D., CEO of Lisata Therapeutics, Inc.
Disclaimer
This article is for informational purposes only and does not constitute investment advice or a solicitation to purchase or sell any securities. The information is based on Lisata Therapeutics, Inc.’s SEC filings as of June 8, 2026. Investors are urged to read all relevant documents, including the Schedule TO and Schedule 14D-9, as and when they become available, and to consult with their financial advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties, and actual results may differ materially from those described herein.
